Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C

Internal Medicine

Volumn 46, Issue 22, 2007, Pages 1827-1832

  Arase, Yasuji ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Akuta, Norio ^a   Kawamura, Yusuke ^a   Kobayashi, Masahiro ^a   Hosaka, Tetsuya ^a   Sezaki, Hitomi ^a   Yatsuji, Hiromi ^a   Kobayashi, Mariko ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Peginterferon; Ribavirin; Side effects

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DECREASED APPETITE; DIABETES MELLITUS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; FRACTURE; GENOTYPE; HEART ARRHYTHMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; JAPANESE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; NONHUMAN; PATIENT COMPLIANCE; PNEUMONIA; PROSPECTIVE STUDY; PRURITUS; RETINA HEMORRHAGE; RETINOPATHY; SIDE EFFECT; THROMBOCYTOPENIA; VERTIGO;

ADOLESCENT; ADULT; AGE FACTORS; AGED; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT REFUSAL; VIRAL LOAD;

EID: 36749016632     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.0289     Document Type: Article

References (17)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355, 2004.
4. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25: 283-291, 1996.
5. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 36: S237-244, 2002.
6. Iwasaki Y, Ikeda H, Arald Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 43: 54-63, 2006.
7. Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 117: 408-413, 1999.
8. McHutchison JG, Manns M, Patel K, et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061-1069, 2002.
9. Shiffinan ML, Di Bisceglie AM, Lindsay KL, et al. Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126: 1015-1023, 2004.
10. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during refreatment in patients with chronic hepatitis C. Gastroenterology 132: 103-112, 2007.
11. Albadalejo J, Alonso R, Antinozzi R, et al. Multicenter evaluation of the Cobas Amplicor HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 36: 862-865, 1998.
12. Doglio A, Laffont C, Caroli-Bose FX, et al. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Chn Microbiól 37: 1567-1569, 1999.
13. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes; an investigation of type-specific differences in geographic origin and disease. Hepatology 19: 13-18, 1994.
14. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 1513-1520, 1994.
15. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38: 645-652, 2003.
16. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 131: 1040-1048, 2006.
17. Krawitt EL, Gordon SR, Grace ND, et al. for the New York New England Study Team. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 101: 1268-1273, 2006.